A single preoperative oral dose of XXXX , a new @entity3840 specific inhibitor, relieves post-oral surgery or bunionectomy @entity158 .

@entity1 @entity17852 @entity1337 @entity158 @entity3840 @entity282
BACKGROUND: The trend toward day-case surgery, with discharge on oral medication, has highlighted the need for effective and safe analgesics that facilitate a rapid recovery and discharge time. This study evaluated the analgesic efficacy, dose dependency, duration of action, and safety of the @entity3840 specific inhibitor, @entity17852 , administered before oral or orthopedic surgery. METHODS: Eligible healthy adult @entity1 were scheduled to undergo either extraction of two impacted third molar teeth (n = 284) or bunionectomy surgery (n = 223) with local anesthesia in two randomized, double-blind, placebo-controlled studies conducted at three centers in the United States. @entity1 received a single, preoperatively administered oral dose of placebo or 10 (oral surgery only), 20, 40, or 80 mg @entity17852 . Analgesic efficacy was assessed postoperatively, over a 24-h treatment period, or until the @entity1 required rescue medication. Efficacy measures included time to rescue medication, proportion of @entity1 requiring such rescue, @entity158 intensity, and the @entity1 's Global Evaluation of Study Medication. RESULTS: In both studies, all doses of @entity17852 produced @entity1337 with a duration (time to rescue @entity1337 ) and magnitude ( @entity158 Intensity, @entity1 's Global Evaluation) significantly greater than placebo. A dose-dependent effect was observed up to 40 mg @entity17852 , with an 80-mg dose providing no additional analgesic benefit. In both models, all doses of @entity17852 were well tolerated, with no clinically significant treatment-related gastrointestinal, renal, or platelet-derived adverse events, and no evidence of a dose-related increase in adverse events. CONCLUSIONS: Preoperative orally administered @entity17852 provides well-tolerated and effective @entity1337 for mild to moderate @entity282 .
